Oncimmune (LON:ONC) Releases Quarterly Earnings Results

Oncimmune (LON:ONC) posted its quarterly earnings data on Monday. The company reported GBX (4.72) (($0.06)) EPS for the quarter, Digital Look Earnings reports. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

Oncimmune Price Performance

Shares of ONC traded up GBX 0.39 ($0.00) during mid-day trading on Wednesday, reaching GBX 8.01 ($0.10). The stock had a trading volume of 1,438,537 shares, compared to its average volume of 304,037. The business has a fifty day moving average of GBX 13.37 and a 200 day moving average of GBX 14.80. The company has a debt-to-equity ratio of 806.85, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market cap of £5.94 million, a price-to-earnings ratio of -267.13 and a beta of 1.19. Oncimmune has a 12 month low of GBX 7.50 ($0.09) and a 12 month high of GBX 31 ($0.39).

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.